Related by context. All words. (Click for frequent words.) 80 RECIST Response Evaluation Criteria 75 Antitumor Activity 74 Response Evaluation Criteria 74 Castration Resistant Prostate Cancer 74 Renal Cell Carcinoma 73 Advanced Melanoma 73 Newly Diagnosed Multiple Myeloma 73 Relapsing Multiple Sclerosis 73 Prolongs Survival 73 Solid Tumors criteria 73 Myelodysplastic Syndromes 73 Oral Fingolimod 73 Tyrosine Kinase Inhibitor 73 Metastatic Colorectal Cancer 73 Metastatic Renal Cell Carcinoma 72 Well Tolerated 72 Solid Tumours 72 Preclinical Data 72 Severe Sepsis 72 Advanced Renal Cell 72 Progenitor Cells 72 Pulmonary Arterial Hypertension 72 Clinical Trial Results 72 Relapsed Refractory 72 Phase 2b Clinical Trial 72 Survival Benefit 72 Phase 2b Study 72 Hormone Refractory Prostate Cancer 71 Acute Ischemic Stroke 71 Clinical Outcome 71 II Clinical Trial 71 Chronic Lymphocytic Leukemia 71 Chronic Hepatitis C 71 Metastatic Prostate Cancer 71 Tumor Response 71 Venous Thromboembolism 71 Complicated Skin 71 Study Evaluating 71 Autologous Stem Cell Transplantation 71 Targeted Therapy 71 Colorectal Cancer Patients 71 Adjuvant Chemotherapy 71 Anti Tumor Activity 71 Meta Analysis 70 Hepatocellular Carcinoma 70 Anti Tumor 70 Adjuvant Therapy 70 Advanced Solid Tumors 70 Rheumatoid Arthritis Patients 70 Metastatic Melanoma 70 Invasive Breast Cancer 70 Previously Treated 70 Mouse Model 70 Controlled Trial 70 Dose Escalation 70 Patients Receiving 70 Decitabine 70 Phase IIb Clinical Trial 70 Improve Survival 70 Neoadjuvant Chemotherapy 70 Follicular Lymphoma 70 Hypercholesterolemia 70 Drug Candidate 70 Investigational Drug 70 Novel Oral 70 Improves Survival 70 Novel Antibiotic 69 See CLINICAL PHARMACOLOGY 69 Multiple Myeloma Patients 69 Investigational Agent 69 Diabetic Patients 69 Phase 2a Trial 69 Randomized Phase 69 Oral Mucositis 69 Brain Metastases 69 Immunogenicity 69 Phase III Clinical Trial 69 Subgroup Analysis 69 Preclinical Study 69 Improves Outcomes 69 Randomized Clinical Trial 69 Renal Function 69 Acute Coronary Syndromes 69 Cutaneous T 69 Advanced Colorectal Cancer 69 Bortezomib 69 Ischemic Stroke 69 Overactive Bladder 69 Adjunctive Therapy 69 Placebo Controlled Trial 69 Randomized Controlled Trials 69 Estrogen Receptor 69 Malignant Melanoma 69 Acute Myocardial Infarction 69 Localized Prostate Cancer 69 Ventricular Arrhythmias 69 Dendritic Cells 69 Novel Mechanism 69 JAK Inhibitor 69 Diffuse Large B 69 Meets Primary Endpoint 69 Severe Asthma 69 HCV Protease Inhibitor 69 Antiviral Activity 69 Treating Chronic 69 RNAi Therapeutic 69 Patients Treated With 69 Patients Treated 69 Bladder Cancer 69 Relapsed Multiple Myeloma 68 Randomized Double blind 68 Complete Remission 68 Advanced Prostate Cancer 68 Refractory Hodgkin Lymphoma 68 Improved Survival 68 familial amyloidotic polyneuropathy FAP 68 Hematological Malignancies 68 Kinase Inhibitor 68 Myocardial Ischemia 68 Immune Responses 68 Gastric Cancer 68 Elderly Patients 68 Cardiovascular Outcomes 68 Prospective Randomized 68 Benign Prostatic Hyperplasia 68 Combination Treatment 68 Phase IIb Trial 68 Chronic Myelogenous Leukemia 68 Preclinical Models 68 Treatment Outcome 68 Epidermal Growth Factor Receptor 68 Clinical Trial Evaluating 68 Leukemias 68 Ranolazine 68 Therapeutic Potential 68 Soft Tissue Sarcoma 68 Tolerability 68 Immunomodulatory 68 Randomized Double Blind 68 Carotid Endarterectomy 68 Monotherapy 68 Sustained Efficacy 68 Advanced Ovarian Cancer 68 Diabetic Nephropathy 68 Chronic Myeloid Leukemia 68 SABCS 68 Investigational Compound 68 Statistically Significant 68 Malignancies 68 Phase III Trial 68 Cognitive Impairment 68 Taxane 68 Pooled Analysis 68 Is Well Tolerated 68 Present Preclinical Data 68 HCV Genotype 67 Golimumab 67 Risk Stratification 67 Bevacizumab 67 Patients Undergoing 67 Acute Heart Failure 67 Presents Preclinical Data 67 Novel Therapeutic 67 Interferon Beta 67 Relapsed Refractory Multiple Myeloma 67 Anticancer Drugs 67 Sipuleucel T 67 INCB# [003] 67 Clinical Outcomes 67 Phase 2b Trial 67 Sapacitabine 67 Diabetic Neuropathy 67 Cell Lymphoma 67 Septic Shock 67 Pharmacokinetic Study 67 Emerging Therapies 67 Patient Outcomes 67 Demonstrated Significant 67 Phase III Trials 67 Investigational Treatment 67 Virologic 67 Universal Flu Vaccine 67 Ischemic 67 Adjuvant Treatment 67 Hemodialysis Patients 67 Renal Tumors 67 Anthracycline 67 Disease Progression 67 Myelodysplastic Syndrome 67 Proves Effective 67 Fungal Infections 67 Partial Onset Seizures 67 Reduces Mortality 67 PKC# 67 Cardiotoxicity 67 Solid Tumor 67 Treatment Naïve 67 MGd 67 Chronic Lymphocytic Leukemia CLL 67 Renal Cancer 67 Allergic Rhinitis 67 Pharmacokinetics PK 67 Atopic Dermatitis 67 Radical Prostatectomy 67 Randomized Phase II 67 Late Breaker 67 Bone Metastases 67 Enzyme Replacement Therapy 67 Prognostic Value 67 Resistant Hypertension 67 Myocardial Infarction Study 67 Antigen Specific 67 Pegylated Liposomal Doxorubicin 67 MEK Inhibitor 67 invasive aspergillosis 67 Postmenopausal Women 67 Hypertensive Patients 67 Chemoradiation 67 Systematic Review 67 Treatment Experienced 67 Allogeneic 67 Chronic Hepatitis B 67 KRN# 67 Androgen Deprivation Therapy 67 Adenoma 67 Combination Therapy 67 Recurrent Breast Cancer 67 Immune Mediated 67 EGFR HER2 67 Idiopathic Pulmonary Fibrosis 67 Cardiovascular Events 67 Circulating Tumor Cells 67 Radiofrequency Ablation 67 Single Dose 67 Chronic Renal Failure 67 Targeted Therapies 67 ISTODAX ® 67 Multicenter Study 67 Functional Outcomes 67 Orally Active 67 Antiangiogenic 67 Liver Metastases 67 Hsp# Inhibitor 67 Initiate Phase 67 Predict Risk 67 Relapsed 67 Hematologic 67 Heart Failure Patients 67 Fondaparinux 67 Advanced Pancreatic Cancer 67 Antiviral Therapy 67 Novel Small Molecule 67 Autoimmune Disease 67 Double Blind Placebo 67 Plus Ribavirin 67 Randomized Double Blind Placebo 66 Clinical Trial Data 66 Hepatotoxicity 66 Myelofibrosis 66 Chronic Heart Failure 66 Hormone Receptor Positive 66 bortezomib refractory 66 Pharmacodynamics 66 Insulin Resistance 66 Nymox NX 66 Randomized Study 66 Non Responders 66 RNAi Therapeutics 66 Long Term Efficacy 66 Score TOS 66 Urinary Incontinence 66 Immunosuppression 66 Contrast Agents 66 Thrombolysis 66 Malignant Glioma 66 Monoclonal Antibody 66 Dual Antiplatelet Therapy 66 Lung Cancer Trial 66 Trastuzumab 66 Lung Cancer Drug 66 Critically Ill Patients 66 Placebo Controlled Study 66 Eculizumab 66 Pivotal Phase III 66 Pemetrexed 66 Cell Transplants 66 Breast Cancer Treatment 66 Controlled Study 66 STRIDE PD 66 achieved CCyR 66 Epratuzumab 66 Novel Inhibitor 66 Randomized Controlled 66 Chemotherapeutic Agents 66 Demonstrates Efficacy 66 Natalizumab 66 Aflibercept 66 Dose Ranging Study 66 Unfractionated Heparin 66 Shows Efficacy 66 Prospective Multicenter 66 Neuroprotective Effects 66 Initiates Clinical Trial 66 Omacetaxine 66 Etanercept 66 Hematologic Malignancies 66 B Cell Lymphoma 66 Gene Mutation 66 recurrent glioblastoma multiforme 66 ST Segment Elevation 66 Treating Heart Failure 66 Small Molecule 66 Aurora Kinase 66 Randomized Controlled Trial 66 Shows Promising 66 Epoetin Alfa 66 Treatment Reduces 66 fosbretabulin 66 Relapsing Remitting Multiple Sclerosis 66 Demonstrates Positive 66 Breast Cancer Recurrence 66 sunitinib Sutent 66 Knee Osteoarthritis 66 Subtypes 66 Nicotine Vaccine 66 Hepatitis C Virus 66 Treatment Regimen 66 Platelet Inhibition 66 Mouse Models 66 Receives Orphan Drug Designation 66 Dapagliflozin 66 Initiate Clinical Trial 66 Pediatric Patients 66 Hematological 66 Antitumor 66 Cognitive Function 66 Treatment Naive 66 Immunotherapeutic 66 Demonstrates Potent 66 Genotypes 66 PEG IFN 66 Newly Diagnosed 66 Anticancer Activity 66 Angiographic 66 HDAC Inhibitor 66 Rheumatoid Arthritis RA 66 Vaccine Adjuvant 66 Efficacious 66 Treatment Resistant 66 Neoadjuvant 66 Retreatment 66 Node Positive 66 Demonstrates Sustained 66 Beneficial Effects 66 Clostridium difficile Infection 66 EBMT criteria 66 Autoimmune Diseases 66 Interferon Gamma 66 Azacitidine 66 viral kinetics 66 Hematological Cancers 66 Prostate Cancer Patients 66 Randomized Clinical Trials 65 Clinical Efficacy 65 Metastatic Breast Cancer 65 Lung Cancer Patients 65 Patients Suffering 65 5 Fluorouracil 65 Generalized Anxiety Disorder 65 Unresectable 65 Capecitabine 65 Disease Severity 65 Tyrosine Kinase Inhibitors 65 Breast Tumors 65 Demonstrates Significant 65 Treatment Naive Patients 65 HER2 Positive Breast Cancer 65 gefitinib Iressa 65 Blood Cancers 65 Tiotropium 65 Kidney Function 65 Therapeutic Efficacy 65 Left Ventricular 65 ritonavir boosted 65 Renal Impairment 65 Clinical Evaluation 65 Atypical Hemolytic Uremic Syndrome 65 Peripheral Blood 65 Doxil ® 65 Pivotal Study 65 Ovarian Cancer Patients 65 Kidney Transplantation 65 Disease Modifying 65 Platinol ® 65 Biomarker Study 65 Infected Patients 65 Peginterferon Alfa 2a 65 Liposomal 65 Surgical Treatment 65 Inflammatory Markers 65 First Patient Enrolled 65 Dasatinib 65 Statin Therapy 65 Naive Patients 65 Pralatrexate 65 Glufosfamide 65 Prophylactic Treatment 65 novel VDA molecule 65 Systemic Delivery 65 stage IIIB 65 Skeletal Muscle 65 Tocilizumab 65 Completes Patient Enrollment 65 Adalimumab 65 Significantly Improved 65 Pivotal Phase 65 Pharmacokinetic 65 Tumor Growth 65 Stem Cell Transplants 65 Cytotoxicity 65 Poster Discussion 65 Novel Therapies 65 Romidepsin 65 Potent Inhibitor 65 Differential Diagnosis 65 Intravesical 65 Versus Placebo 65 Gemcitabine 65 Dose Response 65 Recombinant Human 65 CYT# potent vascular disrupting 65 Diabetic Foot Ulcer 65 Physical Function 65 Endometrial Cancer 65 Osteoarthritis Patients 65 Pharmacodynamic 65 Drug Resistant 65 Radioimmunotherapy 65 Previously Untreated 65 Double Blind Randomized 65 interferon gamma 1b 65 HCV SPRINT 65 Microalbuminuria 65 Invasive Fungal Infections 65 alfa 2a 65 Bosentan 65 Pertuzumab 65 Kidney Transplants 65 Protease Inhibitor 65 Skin Lesions 65 Genetic Variation 65 Antiplatelet Therapy 65 Combination REOLYSIN R 65 Pivotal Trials 65 metastatic malignant 65 Intervention Trial 65 ACTEMRA TM 65 Initiates Clinical 65 First Patient Dosed 65 Prognostic Significance 65 Phase Ib Clinical Trial 65 ALN HPN 65 Carotid Stenting 65 Genes Predict 65 Inflammatory Pain 65 ALN TTR 65 Cholinesterase Inhibitors 65 Stent Restenosis 65 IND Application 65 Chemotherapy Improves 65 CCyR 65 Poster Presentation 65 Myelodysplastic Syndrome MDS 65 Liver Cancer 65 Autoimmune Disorders 65 Study Showed 65 Cancer Therapies 65 Virus Infection 65 FOLFOX6 65 Appears Safe 65 metastatic neuroendocrine tumors 65 Genes Involved 65 Phase IIa Clinical Trial 65 Trodusquemine MSI 65 Breast Density 65 Kidney Transplant Recipients 65 SPRYCEL ® 65 Treatment Naive HIV 65 Aggressive Prostate Cancer 65 Unstable Angina 65 Tumor Cells 65 Melphalan 65 Hospitalized Patients 65 icatibant 65 Gastrointestinal Stromal Tumors 65 Modulates 64 galiximab 64 Stereotactic Body Radiation Therapy 64 metastatic GIST 64 Vitro Activity 64 Hepatic Encephalopathy 64 JAK2 Inhibitor 64 Peginterferon 64 vitro cytotoxicity 64 Receptor Antagonists 64 Drug Shows Promise 64 Pegylated Interferon 64 Potent Anti 64 Progressive Multifocal Leukoencephalopathy 64 Postmenopausal Osteoporosis 64 Bosutinib 64 Major Depressive Disorder 64 FOLOTYN ® 64 Interferon Alfa 64 Percutaneous Coronary Intervention 64 dasatinib Sprycel ® 64 Non Invasive 64 Aliskiren 64 Phase 2a Clinical Trial 64 Heterozygous Familial Hypercholesterolemia 64 FOLPI 64 Pivotal Trial 64 Successfully Treated 64 Treated Patients 64 Abiraterone Acetate 64 Oral Presentations 64 AA Amyloidosis 64 Systemic Lupus Erythematosus SLE 64 Oral Formulation 64 Successfully Completes Phase 64 colorectal liver metastases 64 Anticancer Drug 64 Dose Escalation Study 64 Brentuximab Vedotin SGN 64 Glatiramer Acetate 64 Metabolic Disorder 64 Osteoporosis Treatment 64 Immunomedics Announces 64 transthyretin TTR mediated amyloidosis 64 Myocardial Infarction 64 Nonalcoholic Fatty Liver Disease 64 Tumor Progression 64 Protein Biomarkers 64 Hepatitis C Genotype 64 Diabetic Macular Edema 64 dual endothelin receptor antagonist 64 Protease Inhibitors 64 relapsed MM 64 Mimetics 64 Ocrelizumab 64 ExTRACT TIMI 64 Pharmacokinetics 64 Aggressive Reduction 64 Study Demonstrates 64 Paroxysmal Nocturnal Hemoglobinuria PNH 64 RECIST criteria 64 Bipolar Mania 64 IND Filing 64 Fewer Side Effects 64 Factor Receptor 64 Long Term Outcomes 64 Shows Promise Against 64 Nebulized 64 Inflammatory Disease 64 Antifungals 64 Antipsychotic Medications 64 EURIDIS 64 GW# [003] 64 Combo Therapy 64 huN# DM1 64 Serious Infections 64 Parathyroid Hormone 64 Severity MSCS score 64 Newly Diagnosed Breast Cancer 64 R lenalidomide 64 Renal Cell Carcinoma RCC 64 Rotavirus Vaccine 64 Kinase Inhibitors 64 PSMA ADC 64 Left Ventricular Dysfunction 64 Nilotinib 64 PEG SN# 64 Sentinel Lymph Node Biopsy 64 Atypical Antipsychotics 64 Atypical Antipsychotic 64 Thromboembolism 64 Carfilzomib 64 Randomized Trials 64 Growth Hormone Deficiency 64 Signaling Pathways 64 Tumor Microenvironment 64 Novel Compound 64 Receptor Agonist 64 Patient Enrollment 64 Blocked Arteries 64 Prostate Cancer Treatment 64 Lupus Drug 64 Traficet EN 64 Prospective Randomized Trial 64 B Cell Malignancies 64 Rectal Cancer 64 Commonly Used 64 Signaling Pathway 64 Lung Tumors 64 Prognostic Factors 64 Multicenter Trial 64 Replacement Therapy 64 Anti Angiogenic 64 Teriflunomide 64 Tolvaptan 64 Coronary Arteries 64 mapatumumab 64 Lung Cancer Survival 64 Insulin Glargine 64 Renal Insufficiency 64 Rigel R# 64 Minimally Invasive Treatment 64 hyperphenylalaninemia HPA due 64 Cytotoxic 64 Antipsychotic 64 Obese Patients 64 Anti TNF 64 ST Elevation Myocardial 64 pharmacodynamic parameters 64 Active Rheumatoid Arthritis 64 ASCO GI 64 Chronic Sinusitis 64 chemoradiation therapy 64 Antitumor activity 64 Therapeutic Targets 64 Suicidality 64 Myeloma Patients 64 Fast Track Status 64 Lung Injury 64 Allogeneic Stem 64 Endothelial Cells 64 ACE Inhibitors 64 Liver Failure 64 Depressive Symptoms 64 lexidronam injection 64 Glucocorticoid 64 Lymphoid 64 sipuleucel T 64 Cancer Immunotherapy 64 Cyclooxygenase 2 64 Ischaemic 64 cinacalcet 64 Granted Orphan Drug 64 Acute Decompensated Heart Failure 64 Prostate Biopsy 64 antibody MAb 64 Trial Evaluating 64 Safinamide 64 complement inhibitor eculizumab 64 superficial bladder cancer 64 hA# 64 Outpatient Setting 64 DNA Methylation 64 haematologic 64 Carboplatin Paclitaxel 64 Ejection Fraction 64 Antisense Drug 64 TLK# 64 Diagnostic Criteria 64 Liver Tumors 64 CIMZIA TM certolizumab pegol 64 Oligonucleotides 64 pertuzumab 63 Polymerase Inhibitor 63 Telbivudine 63 Premature Infants 63 Lipid Levels 63 Hospital Acquired Pneumonia 63 Novel Treatments 63 Adult Stem Cell Therapy 63 Percutaneous Tibial Nerve Stimulation 63 Anti Inflammatory Drug 63 Files IND 63 Poster Presentations 63 polycythemia vera PV 63 Efficacy Trial 63 Pathogenesis 63 Carcinoma 63 Lung Cancers 63 Fluorouracil 63 Breast Tissue 63 Therapeutic Antibody 63 paclitaxel cisplatin 63 Combination Clinical Trial 63 Therapeutic Antibodies 63 Degarelix 63 Cethromycin 63 Selective Cardiac Myosin Activator 63 Enzastaurin 63 peripheral blood mononuclear 63 Spectrum Pharmaceuticals Announces 63 Cardiac Resynchronization 63 BEXXAR Therapeutic Regimen 63 PEGylated anti 63 HER2 Positive 63 Cyclophosphamide 63 myelofibrosis polycythemia vera 63 Inflammatory Diseases 63 docetaxel Taxotere ® 63 Vandetanib 63 Long Term Survival 63 TNF Tumor Necrosis Factor 63 ARIXTRA R 63 PEGylated Fab fragment 63 BiTE Antibody 63 Cell Lung Cancer 63 Cancer Stem Cells 63 Multicenter Randomized 63 #F FDG PET CT 63 Clinical Practice Guideline 63 RECIST 63 Newly Diagnosed Patients 63 Systemic Sclerosis 63 Heart Transplant Recipients 63 TNF Blockers 63 Neuropathic Pain 63 Zoledronic Acid 63 baseline LDH 63 Schizophrenia Treatment 63 Ozarelix 63 Solid Tumors RECIST 63 standard chemotherapy regimen 63 Reduced Risk 63 Neuroendocrine Tumors 63 Diagnostic Tests 63 Primary Hypercholesterolemia 63 Oral Insulin 63 Rate ORR 63 histone deacetylase HDAC inhibitor 63 Pegasys ® 63 rFVIIa 63 Medication Adherence 63 Blinatumomab 63 Mycophenolate Mofetil 63 Clinical Study 63 Tumor Cell 63 Critical Limb Ischemia CLI 63 Humanized Anti 63 Inhaled Corticosteroids 63 Lenalidomide 63 Gene Linked 63 Experimental Vaccine 63 Abciximab 63 Inhibits 63 Blood Pressure Lowering 63 Induction Chemotherapy 63 Prophylaxis 63 Acute Pancreatitis 63 Activator CK # 63 Alemtuzumab 63 J Am Coll 63 Thrombotic 63 C1 Inhibitor 63 Chronic HCV 63 NDA Submission 63 Systemic Lupus Erythematosus 63 Neuroprotection 63 Pharmacogenetic 63 Inflammatory Arthritis 63 bevacizumab Avastin ® 63 5 FU leucovorin 63 Pulmonary Hypertension 63 refractory CLL 63 Renal Anemia 63 AACR NCI EORTC 63 Diabetic Retinopathy 63 Hepatocellular Carcinoma HCC 63 oral prodrug 63 Darbepoetin Alfa 63 adalimumab Humira 63 Predict Response 63 nab paclitaxel 63 CTAP# Capsules 63 Erlotinib 63 Lymphocytic 63 Secondary Hyperparathyroidism 63 Therapy Improves 63 Phase III Clinical Trials 63 Bivalirudin 63 leukemia CLL 63 recurrent glioma 63 CLINICAL PHARMACOLOGY 63 unresectable tumors 63 Lupus Nephritis 63 Periodontal Disease 63 Prostatic 63 bFGF 63 HuMax EGFr 63 Tumor Targeting 63 Vildagliptin 63 Regenerative Cells 63 follicular lymphomas 63 Comorbidities 63 GLIADEL R Wafer 63 Tumor Necrosis Factor 63 invasive candidiasis 63 Genes Linked 63 Regimens 63 Breast Cancer Cells 63 LENALIDOMIDE 63 Nesiritide 63 Improve Outcomes 63 abacavir Ziagen 63 Breast Cancers 63 Total Knee Arthroplasty 63 HER2 positive metastatic breast 63 Paraplatin ® 63 INVEGA ® 63 Genetic Markers 63 Chronic Bronchitis 63 bronchial hyperresponsiveness 63 Hematopoietic Stem Cell Transplantation 63 resected pancreatic cancer 63 Cancer Cells 63 Induces 63 erlotinib Tarceva ® 63 Cholesterol Lowering Drug 63 Antiplatelet 63 thalidomide Thalomid 63 pan HDAC inhibitor 63 Aromatase Inhibitors 63 Fulvestrant 63 Radiofrequency Ablation RFA 63 Squamous 63 JAK2 V#F 63 Immunohistochemistry 63 Tezampanel 63 cytogenetic response 63 CT Angiography 63 papillary renal cell carcinoma 63 T#I [002] 63 Mortality Risk 63 Hepatic 63 Brain Tumors 63 Fracture Risk 63 Intervention Effectiveness 63 Protein Expression 63 Radiation Dose 63 Rheumatoid Arthritis 63 Abstract Number 63 sorafenib tablets 63 Slow Progression 63 Non Alcoholic Fatty 63 Intracranial Aneurysms 63 Surgical Procedures 63 mycophenolate mofetil 63 Lubiprostone 63 Enoxaparin 63 NSABP B 63 Aptamer 63 Cervical Dysplasia 63 Hedgehog Pathway 63 Confirmatory Phase 63 Uterine Fibroid Embolization 63 selective modulator 63 Potent Antiviral Activity 63 Demonstrates Potential 63 CIMZIA TM 63 metastatic RCC 63 treatment naive genotype 63 Pneumococcal Vaccine 63 Juvenile Idiopathic Arthritis 63 Lymphoma Patients 63 Therapeutic Approaches 63 relapsing multiple sclerosis 63 Cell Transplant 63 Renal Artery 63 Rheumatoid Arthritis Drug 63 Gemzar ® 63 serum phosphate 63 Less Invasive 63 Inhaled Nitric Oxide 63 IL# PE#QQR 63 Vertebral Fractures 63 Pegylated 63 MAGE A3 ASCI 63 Cardiogenic Shock 63 Achieves Primary Endpoint 63 Kidney Failure 63 Intracerebral Hemorrhage 63 Angiotensin Converting Enzyme 63 ZOLINZA 63 Hepatitis C Infection 63 Angiogenic 63 Neovascular Age Related Macular 62 Treat Anemia 62 inhibitor RG# 62 Viral Suppression 62 Glycemic Control 62 Sangamo BioSciences Announces 62 Beta Blocker 62 Increased Mortality 62 immunohistochemical staining 62 Phase 1b Clinical Trial 62 atypical Hemolytic Uremic Syndrome 62 Vaccine Adjuvants 62 Liver Injury 62 Phase 2a Study 62 Community Acquired Pneumonia 62 Fixed Dose 62 Bloodstream Infections 62 BARACLUDE ® 62 Gout Drug 62 Anticoagulation 62 Pivotal Clinical Trial 62 Mg Uk 62 Sleep Disturbances 62 Endocrine Therapy 62 Cancer Vaccines 62 Relapsed Refractory Aggressive 62 Intravascular 62 TO AVOID PREGNANCY WHILE 62 Protein Involved 62 Thromboembolic 62 Post Operative 62 Low Dose 62 mg BID dose 62 Bare Metal Stents 62 samarium Sm 62 Initiates Phase III 62 Bioavailability 62 Blind Placebo Controlled Trial 62 Amrubicin 62 APTIVUS r 62 sorafenib Nexavar 62 Telaprevir VX 62 Cholesterol Levels SPARCL 62 Chronic Pelvic Pain 62 Completes Enrollment 62 4mg/kg 62 liposome injection 62 Pafuramidine 62 Improved Outcomes 62 FDA Approvals 62 Reports Preclinical Data 62 Cystectomy 62 Drug Combo 62 intravesical infusion therapy 62 FDG-PET/CT 62 Etiology 62 Refractory Angina 62 Therapeutic Effects 62 NCCTG N# 62 Bucindolol Based 62 Index CDAI 62 Presents Positive 62 Dupuytren Contracture 62 refractory chronic lymphocytic 62 Clusterin 62 Receives Orphan Drug 62 Tesetaxel 62 Contrast Enhanced 62 receptor tyrosine kinase inhibitor 62 Mantle Cell Lymphoma 62 Smooth Muscle 62 Significantly Improves 62 Hemorrhagic Stroke 62 humanized anti 62 Demonstrate Significant 62 Immune Cell 62 Neural Stem Cells 62 Cytogenetic 62 Insulin Therapy 62 Transdermal Patch 62 Vidaza azacitidine 62 Coronary Angiography 62 Treatment Regimens 62 Induction Therapy 62 Autoantibodies 62 Non inferiority 62 Robotic Assisted 62 eosinophilic asthma 62 PRTX 62 SAR# [004] 62 Cardiomyocytes 62 8mg/kg 62 cell lymphoma CTCL 62 Stem Cell Transplant 62 Oral Cavity 62 Topline Results 62 severe neutropenia 62 azacytidine 62 huC# DM4 62 plasma pharmacokinetics 62 imatinib resistant 62 Non Inferiority 62 Small Intestine 62 Thyroid Hormone 62 Fecal Incontinence 62 insulin glulisine 62 hypereosinophilic syndrome 62 Treating Depression 62 TLR antagonist 62 Tanespimycin